Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03799627 · ClinicalTrials.gov registry record · Phase 2
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
A Phase 2 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT03799627 is a Phase 2 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 175 participants.
The verdict
NCT03799627, a Phase 2 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy.
Interventions
- DRUG Epoetin Alfa
- DRUG Vadadustat
- DRUG Vadadustat TIW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03799627
The ClinicalTrials.gov registry entry for NCT03799627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Epoetin Alfa is the first listed.
NCT03799627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03799627 about?
NCT03799627 is a clinical study titled "Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa". This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy.
What is the current status of trial NCT03799627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2019-01-31. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03799627?
The interventions under investigation include: Epoetin Alfa (DRUG), Vadadustat (DRUG), Vadadustat TIW (DRUG).
Who is sponsoring clinical trial NCT03799627?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.